Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s ...

Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.

After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...

Last year, there was further disappointment for the company after another drug partnered with Biogen, Zurzuvae (zuranolone), was approved by the FDA for postpartum depression (PPD), but turned ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Copyright 2024 The Associated Press. All Rights Reserved. The U.S. military trained him in explosives and battlefield tactics. But after two tours in Iraq, Chris ...